News | Cardiovascular Surgery | February 18, 2022

Evonik invests in U.S. start-up offering medical device to improve patient recovery after open-chest surgery

CircumFix’s innovative orthopedic device closes and stabilizes the sternum after surgery

Evonik Venture Capital has invested in CircumFix Solutions, a Tennessee-based start-up that has developed a new sternal closure device to improve patient recovery after open chest surgery. The patented orthopedic device, made of a high-performance polymer from Evonik, closes and holds the sternum securely together after surgery. 

CircumFix’s medical device is composed of a slender chest plate placed on the sternum and held in place by fasteners that encircle the sternum and are affixed to the plate.


January 18, 2022 – Evonik Venture Capital has invested in CircumFix Solutions, a Tennessee-based start-up that has developed a new sternal closure device to improve patient recovery after open chest surgery. The patented orthopedic device, made of a high-performance polymer from Evonik, closes and holds the sternum securely together after surgery. 

“We are seeing a revolution in implantable medical devices with the shift from metal to high-performance polymers and this investment supports that shift,” said Bernhard Mohr, head of Evonik Venture Capital. “Patients and doctors can benefit enormously from a technology that is safe, reliable and enhances recovery.”

CircumFix’s medical device is composed of a slender chest plate placed on the sternum and held in place by fasteners that encircle the sternum and are affixed to the plate. The construct allows for even “load sharing” of bone and device and restricts motion, which increases stability and reduces pain. Surgeons can close the sternum faster and more easily than with traditional devices. Should a further operation be needed the device can be quickly reopened and closed again. It is safe and comfortable as a permanent implant. In comparison to some metal devices currently on the market, bones and tissue aren’t damaged.

The Evonik material used in the closure device is an implant grade polyether ether ketone, or PEEK. The material is biocompatible - not harmful or toxic to living tissue – and bioinert – it doesn’t initiate a response from the body. These properties as well as being hydrophobic – repelling water – significantly reduce the chance of infection. Being made from PEEK polymer means that the device is transparent to x-rays and therefore doesn’t interfere with post-surgical diagnostics. 

“The investment will deepen our relationships across the medical technology industry and with engineering companies,” said Marc Knebel, head of Medical Systems at Evonik. “At the same time, we can reach U.S. clinical experts in orthopedics, many of whom are less aware of PEEK as an alternative to titanium and stainless steel.”

The U.S. sternal closure device market was estimated at $1.4 billion for 2021 with more than 700,000 procedures performed per year. The market is expected to grow at a compound annual growth rate of 5 percent reaching $1.9 billion by 2026.

The investment will allow Evonik to build on expertise already acquired in implant-grade high-performance polymers. PEEK is already used in spine, skull, jaw and face surgery as well as orthopedics and has high potential to be used in other medical applications. 

Circumfix Solution, Inc. founders Louis Houff and Ken Richardson have more than 50 years combined experience in orthopedic sales, marketing, product development and senior leadership roles. They founded the company in 2020 recognizing the need for improved sternum closure techniques and materials. Houff first conceived of the novel bone fixation and healing concept in 2012 and received his first patent in 2017.

“We are making great progress towards the goal of improving patient recovery,” said Houff, who is also chief executive officer of CircumFix. “With support from Evonik, we will be able to further drive business development forward.”

Evonik markets its high-performance polymer Polyether ether ketone under the name VESTAKEEP.

For more information: https://circumfix.com/

Related Content

Feature | Cardiovascular Surgery

The global vascular graft market size was valued at $4,993.64 million in 2020, and is projected to reach $8,138.68 ...

Home June 14, 2022
Home
News | Cardiovascular Surgery

June 14, 2022 — The Society for Vascular Surgery Vascular Quality Initiative (SVS VQI), a nonprofit organization ...

Home June 14, 2022
Home
News | Cardiovascular Surgery

April 29, 2022 – Paragonix Technologies, Inc., a leading organ preservation provider, announces today groundbreaking ...

Home April 29, 2022
Home
News | Cardiovascular Surgery
February 15, 2022 – A multicenter, retrospective database analysis suggests improved open abdominal aortic aneurysm (AAA ...
Home February 15, 2022
Home
News | Cardiovascular Surgery

February 11, 2022 — Riverside Community Hospital has earned a distinguished three-star rating from The Society of ...

Home February 11, 2022
Home
News | Cardiovascular Surgery

November 23, 2021 — A novel device called venous external support (VEST) may lead to increased longevity and durability ...

Home November 23, 2021
Home
News | Cardiovascular Surgery

November 22, 2021 — The Minneapolis Heart Institute Foundation (MHIF) announced the publication of research showing ...

Home November 22, 2021
Home
News | Cardiovascular Surgery

November 18, 2021 — Moderna Inc. announced positive data from the AstraZeneca-led Phase 2 (EPICCURE) study evaluating ...

Home November 18, 2021
Home
News | Cardiovascular Surgery

November 18, 2021 — People who are on the antiplatelet medication ticagrelor and need coronary artery bypass surgery may ...

Home November 18, 2021
Home
Feature | Cardiovascular Surgery | By Noam Emanuel, Ph.D.

Surgical Site Infection (SSI) prevention remains a high priority for cardiac surgeons whose heroic efforts can be ...

Home June 24, 2021
Home
Subscribe Now